Neurelis Shows Impressive Growth and Innovations in Business Update for 2025

On January 12, 2026, Neurelis, Inc., renowned for its innovative product VALTOCO® (diazepam nasal spray), released a business update that highlights remarkable achievements made in 2025. The company reported an estimated net revenue of $295-$300 million, more than doubling the sales from 2024, and an impressive EBITDA margin surpassing 30%. These updates not only showcase Neurelis' financial resilience but also its commitment to enhance patient care in the rapidly evolving field of epilepsy treatment.

A Strong Financial Position

By the end of 2025, Neurelis maintained a robust financial foundation. With over $175 million in cash and no significant bank debt, the company is well-equipped to invest further in its ongoing research initiatives and product developments. The substantial rise in revenue can largely be attributed to the successful uptake of VALTOCO, especially following the recent FDA label expansion that allows prescription for children aged 2 to 5, providing access to over 12,000 new pediatric patients.

Enhanced Product Portfolio

One of the most impactful components of this update is the expansion of the VALTOCO patent portfolio. The issuance of three new patents strengthens the IP framework around VALTOCO, extending its market exclusivity until 2032. This strategic move not only secures Neurelis' position in the marketplace but also emphasizes the ongoing clinical benefits that VALTOCO provides for patients experiencing frequent seizure episodes. The proprietary formulation employs INTRAVAIL®, a technology that enhances the absorption of the active ingredient, allowing for a quick, non-invasive treatment option.

Innovations in Patient Care

Neurelis' commitment to improving patient care was demonstrated through enhancements made to the commercial packaging of VALTOCO, which came after discovering discrepancies during an independent prescription audit. The new five-dose packaging aligns the amount of medication dispensed with the prescriber's intentions, ensuring that patients receive the proper dosage for their needs, thus improving adherence and overall treatment efficacy. The company has also increased the shelf life of VALTOCO to 32-36 months, further ensuring patient accessibility to this vital medication over an extended period.

A Positive Future for Epilepsy Treatment

Craig Chambliss, Co-Founder and CEO of Neurelis, expressed enthusiasm about the company’s advancements, stating, "We're thrilled with the strides we've made in enhancing patient care options for individuals with epilepsy and their families." He highlighted the FDA's approval for the label expansion of VALTOCO as a significant step in delivering safety and efficacy to an even younger patient demographic. This growth not only provides immediate-use seizure treatments but also solidifies Neurelis’ commitment to the epilepsy community.

With plans for future CNS-focused product developments, Neurelis is strategically positioned to fulfill unaddressed medical needs, further reinforcing the well-being of patients and their caregivers. This update signifies the company's dedication to delivering quality treatments alongside a commitment to financial stability and innovation.

About Neurelis

Neurelis, Inc. is at the forefront of neurological therapeutics, dedicated to developing and commercializing innovative solutions for epilepsy and other neurologic disorders. Their lead product, VALTOCO, is FDA-approved for acute treatment of seizure clusters in patients aged two and older and is part of a broader strategy to address unmet needs within the CNS spectrum.

For more information about Neurelis and VALTOCO, as well as details on their ongoing research programs, visit Neurelis Official Site.